Elena Mata

Dr. Elena Mata

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Science Immunology
Verified
Journal Article
Closed access
EMElena Mata
Elena Mata
RTRaquel Tarancon
Raquel Tarancon
CGClaudia Guerrero
Claudia Guerrero
EMEduardo Moreo
Eduardo Moreo
FMFlavie Moreau
Flavie Moreau
NANacho Aguilo
Nacho Aguilo
Pulmonary BCG administration induces protection against tuberculosis infection via lung macrophage activation.

2 April 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JHJuan Heredero
Juan Heredero
ÁPÁlvaro Peña
Álvaro Peña
EBEsther Broset Blasco
Esther Broset Blasco
BVBEATRIZ BLANDIN VERA
BEATRIZ BLANDIN VERA
DMDiego De Miguel
Diego De Miguel
JGJavier Giménez-Warren
Javier Giménez-Warren
Background/Objectives: Lipid nanoparticles (LNPs) are leading mRNA delivery vehicles, with ionizable lipids (ILs) as their key component. However, the relationship between the IL structure and LNP endogenous organ-targeting is not well understood. In this study, we developed a novel library of biodegradable ILs featuring beta-propionate linkers, which, when incorporated into a four-component LNP formulation, show excellent extrahepatic selectivity and high protein expression. Methods: We explored the impact of structural modifications in the hydrophobic chains and polar-head groups in the ILs while keeping the linkers unchanged. In vivo results were evaluated to examine how structural changes influence the biodistribution to spleen or lungs. LNP formulations were assessed for their protein expression levels and organ-specific targeting. Additionally, protein corona formation by the best-performing LNPs was examined to provide further mechanistic insights. Results: Organ targeting was significantly influenced by structural changes in the ILs, allowing for precise control of the biodistribution between the spleen and lungs. Branched hydrophobic chains demonstrated a higher propensity for spleen targeting, while modifications in the polar-head group could drastically shift biodistribution from the lung to the spleen. This led to the identification of LNPs’ zeta potential as a key determinant of their extrahepatic targeting properties. Notably, ionizable lipid A3T2C7, also known as CP-LC-1495, displayed strong lung selectivity (97%) and high protein expression in lung tissue (1.21 × 108 p/s). Similarly, several promising candidates for spleen-targeting LNPs displayed protein expression levels exceeding 1 × 107 p/s (selectivity >80%). Conclusions: This study elucidates the structure–function relationships of ILs in passive organ-specific mRNA delivery, highlighting how the fine-tuning of hydrophobic chains, polar-head groups, and surface charge (zeta potential) allows for the precise control of LNP endogenous biodistribution, a mechanism influenced by protein corona formation. These findings enable the rational design of targeted LNP systems, enhancing their therapeutic potential for specific organs, such as the spleen and lungs.

16 April 2025 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
ÁPÁlvaro Peña
Álvaro Peña
JHJuan Heredero
Juan Heredero
BBBeatriz Blandín
Beatriz Blandín
EMElena Mata
Elena Mata
DMDiego De Miguel
Diego De Miguel
JGJavier Giménez-Warren
Javier Giménez-Warren
Ionizable lipids are essential components of lipid nanoparticles (LNPs) for efficient mRNA delivery. However, designing them for high protein expression, endosomal escape, and organ targeting is challenging due to complex structure-activity relationships. Here, we present a high-throughput platform for screening ionizable lipids using a two-step, scalable, one-pot reaction. This enabled the synthesis and vivo screening of 91 new lipids, followed by a structure-activity study, leading to the development of CP-LC-0729, which significantly surpasses the MC3 benchmark in protein expression with preliminary studies showing no in vivo toxicity. Additionally, a one-step strategy helped to yield a permanently cationic lipid which was tested in a fifth-lipid formulation, showing a highly selective lung delivery with a 32-fold increase in protein expression in vivo, outperforming current endogenous targeting strategies. All these findings underscore the potential of lipid CP-LC-0729 and our lipid platform in advancing the efficiency and specificity of mRNA delivery systems.

1 July 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
EMElena Mata
Elena Mata
EBEsther Broset
Esther Broset
CMCarlos Matute
Carlos Matute
ASAndrei Stoian
Andrei Stoian
SASusana Adame
Susana Adame
EPEsther Pérez-Herrán
Esther Pérez-Herrán
MRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.

28 October 2024 in Research Square
Verified
Preprint
Open access
PDF file
JGJavier Giménez-Warren
Javier Giménez-Warren
ÁPÁlvaro Peña
Álvaro Peña
JHJuan Heredero
Juan Heredero
EMElena Mata
Elena Mata
BBBeatriz Blandín
Beatriz Blandín
JMJuan Martínez-Oliván
Juan Martínez-Oliván
Ionizable lipids are an essential component of lipid nanoparticles (LNPs) for an efficient mRNA delivery. However, optimizing their chemical structures for high protein expression, efficient endosomal escape, and selective organ targeting remains challenging due to complex structure-activity relationships and multistep synthesis. In this study, we introduce a rapid, high-throughput platform for screening ionizable lipids using a two-step, scalable synthesis involving a one-pot 3-component click-like reaction. This method, herein known as the STAAR approach, standing for Sequential Thiolactone Amine Acrylate Reaction, allowed for the combinatorial synthesis and in vivo screening of 91 novel lipids, followed by a structure-activity study. This led to the development of CP-LC-0729, an ionizable lipid that significantly surpasses the benchmark in protein expression while showing no in vivo toxicity. Additionally, the STAAR lipid platform was further validated by incorporating a one-step strategy to yield a permanently cationic lipid which was tested following a fifth-lipid formulation strategy. The in vivo results showed a highly selective lung delivery with a 32-fold increase in protein expression, outperforming current endogenous targeting strategies. All these findings underscore the potential of lipid CP-LC-0729 and the STAAR lipid platform in advancing the efficiency and specificity of mRNA delivery systems, while also advancing the development of new ionizable lipids.

3 January 2022 in REVISTA IPSUMTEC
Verified
Journal Article
Open access
PDF file
HCHumberto García Castellanos
Humberto García Castellanos
EREricka Berenice Herrera Ríos
Ericka Berenice Herrera Ríos
LHLaura Karina Sáenz Hernández
Laura Karina Sáenz Hernández
RBRubén García Barrios
Rubén García Barrios
EMElena Mata
Elena Mata
La generación y manejo de residuos tanto sólidos como líquidos, han sido motivo de preocupación para las entidades gubernamentales y no gubernamentales dedicadas al cuidado del medio ambiente, por lo que es necesario tomar acciones de contención en una compañía cuya producción principal son los compresores. Esta tiene una alta generación de residuos peligrosos, motivo por el cual es importante dar una disposición adecuada, rápida, segura y que cumpla con la normatividad mexicana aplicable para así asegurar el correcto funcionamiento del almacén de residuos peligrosos de la empresa y así evitar caer en incumplimientos que generen desde un paro de producción hasta aplicación de multas, e incluso un cierre de área o del complejo. Para lograrlo, se desarrolló la clasificación correcta de los residuos peligrosos generados y se actualizó el procedimiento para la administración de estos, utilizando dos estrategias. La primera es dar cumplimiento al reglamento de la Ley General para la Prevención y Gestión Integral de los Residuos [1], y la segunda como empresa generadora de residuos peligrosos, dar cumplimiento a la NOM-052-SEMARNAT-2005[2], que han sido el motivo de realización de este proyecto.